The molecular basis for differential type i interferon signaling

Journal of Biological Chemistry

Volumn 292, Issue 18, 2017, Pages 7285-7294

  Schreiber, Gideon ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTICS; BINDING ENERGY; BINS; CELL DEATH; CHEMICAL ACTIVATION; CYTOLOGY; ENZYME ACTIVITY; GENE EXPRESSION; GLYCOPROTEINS; INTERFERONS; MOLECULES; TISSUE;

ANTIVIRAL ACTIVITIES; BINDING AFFINITIES; CELLULAR CHANGES; EXTRACELLULAR DOMAINS; INTRACELLULAR DOMAIN; PROCESSING STEPS; SURFACE RECEPTORS; TYPE I INTERFERONS;

CELLS;

CELL SURFACE RECEPTOR; INTERFERON; INTERFERON RECEPTOR; STAT1 PROTEIN; STAT2 PROTEIN; ALPHA BETA INTERFERON RECEPTOR; ALPHA INTERFERON; IFNAR1 PROTEIN, HUMAN; IFNAR1 PROTEIN, MOUSE; IFNAR2 PROTEIN, HUMAN; IFNAR2 PROTEIN, MOUSE; STAT PROTEIN;

APOPTOSIS; BINDING AFFINITY; CELL DIFFERENTIATION; CELL PROLIFERATION; FEEDBACK SYSTEM; HUMAN; MOLECULAR BIOLOGY; NONHUMAN; PHENOTYPE; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; GENETICS; IMMUNOLOGY; MOUSE; PHOSPHORYLATION;

ANIMALS; HUMANS; INTERFERON-ALPHA; MICE; PHOSPHORYLATION; RECEPTOR, INTERFERON ALPHA-BETA; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 85018416130     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.R116.774562     Document Type: Review

References (100)

1. Isaacs, A., and Lindenmann, J. (1957) Virus interference. I. The interferon. Proc. R Soc. Lond. B Biol. Sci. 147, 258-267
2. Platanias, L. C. (2005) Mechanisms of type-I-and type-II-interferonmediated signalling. Nat. Rev. Immunol. 5, 375-386
3. Krause, C. D., and Pestka, S. (2015) Cut, copy, move, delete: the study of human interferon genes reveal multiple mechanisms underlying their evolution in amniotes. Cytokine 76, 480-495
4. Harari, D., Abramovich, R., Zozulya, A., Smith, P., Pouly, S., Köster, M., Hauser, H., and Schreiber, G. (2014) Bridging the species divide: transgenic mice humanized for type-I interferon response. PLoS ONE 9, e84259
5. Jaitin, D. A., Roisman, L. C., Jaks, E., Gavutis, M., Piehler, J., Van der Heyden, J., Uze, G., and Schreiber, G. (2006) Inquiring into the differential action of interferons (IFNs): an IFN-α2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-β. Mol. Cell. Biol. 26, 1888-1897
6. Trinchieri, G. (2010) Type I interferon: friend or foe? J. Exp. Med. 207, 2053-2063
7. McNab, F., Mayer-Barber, K., Sher, A., Wack, A., and O'Garra, A. (2015) Type I interferons in infectious disease. Nat. Rev. Immunol. 15, 87-103
8. Samarajiwa, S. A., Forster, S., Auchettl, K., and Hertzog, P. J. (2009) INTERFEROME: the database of interferon regulated genes. Nucleic Acids Res. 37, D852-7
9. Schreiber, G., and Piehler, J. (2015) The molecular basis for functional plasticity in type I interferon signaling. Trends Immunol. 36, 139-149
10. Cohen, B., Novick, D., Barak, S., and Rubinstein, M. (1995) Ligand-induced association of the type I interferon receptor components. Mol. Cell. Biol. 15, 4208-4214
11. Thomas, C., Moraga, I., Levin, D., Krutzik, P. O., Podoplelova, Y., Trejo, A., Lee, C., Yarden, G., Vleck, S. E., Glenn, J. S., Nolan, G. P., Piehler, J., Schreiber, G., and Garcia, K. C. (2011) Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell 146, 621-632
12. Chill, J. H., Quadt, S. R., Levy, R., Schreiber, G., and Anglister, J. (2003) The human type I interferon receptor: NMR structure reveals the molecular basis of ligand binding. Structure 11, 791-802
13. de Weerd, N. A., Vivian, J. P., Nguyen, T. K., Mangan, N. E., Gould, J. A., Braniff, S. J., Zaker-Tabrizi, L., Fung, K. Y., Forster, S. C., Beddoe, T., Reid, H. H., Rossjohn, J., and Hertzog, P. J. (2013) Structural basis of a unique interferon-β signaling axis mediated via the receptor IFNAR1. Nat. Immunol. 14, 901-907
14. Senda, T., Shimazu, T., Matsuda, S., Kawano, G., Shimizu, H., Nakamura, K. T., and Mitsui, Y. (1992) Three-dimensional crystal structure of recombinant murine interferon-β. EMBO J. 11, 3193-3201
15. Li, Z., Strunk, J. J., Lamken, P., Piehler, J., and Walz, T. (2008) The EM structure of a type I interferon-receptor complex reveals a novel mechanism for cytokine signaling. J. Mol. Biol. 377, 715-724
16. Slutzki, M., Jaitin, D. A., Yehezkel, T. B., and Schreiber, G. (2006) Variations in the unstructured C-terminal tail of interferons contribute to differential receptor binding and biological activity. J. Mol. Biol. 360, 1019-1030
17. Piehler, J., Thomas, C., Garcia, K. C., and Schreiber, G. (2012) Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation. Immunol. Rev. 250, 317-334
18. Strunk, J. J., Gregor, I., Becker, Y., Li, Z., Gavutis, M., Jaks, E., Lamken, P., Walz, T., Enderlein, J., and Piehler, J. (2008) Ligand binding induces a conformational change in ifnar1 that is propagated to its membraneproximal domain. J. Mol. Biol. 377, 725-739
19. Lamken, P., Gavutis, M., Peters, I., Van der Heyden, J., Uzé, G., and Piehler, J. (2005) Functional cartography of the ectodomain of the type I interferon receptor subunit ifnar1. J. Mol. Biol. 350, 476-488
20. Sharma, N., Longjam, G., and Schreiber, G. (2016) Type I interferon signaling is decoupled from specific receptor orientation through lenient requirements of the transmembrane domain. J. Biol. Chem. 291, 3371-3384
21. Löchte, S., Waichman, S., Beutel, O., You, C., and Piehler, J. (2014) Live cell micropatterning reveals the dynamics of signaling complexes at the plasma membrane. J. Cell Biol. 207, 407-418
22. Wilmes, S., Beutel, O., Li, Z., Francois-Newton, V., Richter, C. P., Janning, D., Kroll, C., Hanhart, P., Hötte, K., You, C., Uzé, G., Pellegrini, S., and Piehler, J. (2015) Receptor dimerization dynamics as a regulatory valve for plasticity of type I interferon signaling. J. Cell Biol. 209, 579-593
23. Lavoie, T. B., Kalie, E., Crisafulli-Cabatu, S., Abramovich, R., DiGioia, G., Moolchan, K., Pestka, S., and Schreiber, G. (2011) Binding and activity of all human α interferon subtypes. Cytokine 56, 282-289
24. Lamken, P., Lata, S., Gavutis, M., and Piehler, J. (2004) Ligand-induced assembling of the type I interferon receptor on supported lipid bilayers. J. Mol. Biol. 341, 303-318
25. Akabayov, S. R., Biron, Z., Lamken, P., Piehler, J., and Anglister, J. (2010) NMR mapping of the IFNAR1-EC binding site on IFNα2 reveals allosteric changes in the IFNAR2-EC binding site. Biochemistry 49, 687-695
26. Waichman, S., Bhagawati, M., Podoplelova, Y., Reichel, A., Brunk, A., Paterok, D., and Piehler, J. (2010) Functional immobilization and patterning of proteins by an enzymatic transfer reaction. Anal. Chem. 82, 1478-1485
27. Kalie, E., Jaitin, D. A., Abramovich, R., and Schreiber, G. (2007) An interferon α2 mutant optimized by phage display for IFNAR1 binding confers specifically enhanced antitumor activities. J. Biol. Chem. 282, 11602-11611
28. Levin, D., Harari, D., and Schreiber, G. (2011) Stochastic receptor expression determines cell fate upon interferon treatment. Mol. Cell. Biol. 31, 3252-3266
29. Harari, D., Kuhn, N., Abramovich, R., Sasson, K., Zozulya, A. L., Smith, P., Schlapschy, M., Aharoni, R., Köster, M., Eilam, R., Skerra, A., and Schreiber, G. (2014) Enhanced in vivo efficacy of a type I interferon superagonist with extended plasma half-life in a mouse model of multiple sclerosis. J. Biol. Chem. 289, 29014-29029
30. Zhang, K.-J., Yin, X.-F., Yang, Y.-Q., Li, L. L., Xu, Y.-N., Chen, L.-Y., Liu, X.-J., Yuan, S.-J., Fang, X.-L., Xiao, J., Wu, S., Xu, H.-N., Chu, L., Katlinski, K. V., et al. (2017) A potent in vivo antitumor efficacy of novel recombinant type I interferon. Clin. Cancer Res. 10.1158/1078-0432.CCR-16-1386
31. Baruch, K., Deczkowska, A., David, E., Castellano, J. M., Miller, O., Kertser, A., Berkutzki, T., Barnett-Itzhaki, Z., Bezalel, D., Wyss-Coray, T., Amit, I., and Schwartz, M. (2014) Aging-induced type I interferon response at the choroid plexus negatively affects brain function. Science 346, 89-93
32. Mayer-Barber, K. D., Andrade, B. B., Oland, S. D., Amaral, E. P., Barber, D. L., Gonzales, J., Derrick, S. C., Shi, R., Kumar, N. P., Wei, W., Yuan, X., Zhang, G., Cai, Y., Babu, S., Catalfamo, M., et al. (2014) Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature 511, 99-103
33. Sandling, J. K., Garnier, S., Sigurdsson, S., Wang, C., Nordmark, G., Gunnarsson, I., Svenungsson, E., Padyukov, L., Sturfelt, G., Jönsen, A., Bengtsson, A. A., Truedsson, L., Eriksson, C., Rantapää-Dahlqvist, S., Mälarstig, A., et al. (2011) A candidate gene study of the type I interferon pathway implicates IKBKE and IL8 as risk loci for SLE. Eur. J. Hum. Genet. 19, 479-484
34. Sandler, N. G., Bosinger, S. E., Estes, J. D., Zhu, R. T., Tharp, G. K., Boritz, E., Levin, D., Wijeyesinghe, S., Makamdop, K. N., del Prete, G. Q., Hill, B. J., Timmer, J. K., Reiss, E., Yarden, G., Darko, S., et al. (2014) Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature 511, 601-605
35. Gui, J., Gober, M., Yang, X., Katlinski, K. V., Marshall, C. M., Sharma, M., Werth, V. P., Baker, D. P., Rui, H., Seykora, J. T., and Fuchs, S. Y. (2016) Therapeutic elimination of the type 1 interferon receptor for treating psoriatic skin inflammation. J. Invest. Dermatol. 136, 1990-2002
36. Crow, M. K., Olferiev, M., and Kirou, K. A. (2015) Targeting of type I interferon in systemic autoimmune diseases. Transl. Res. 165, 296-305
37. Oon, S., Wilson, N. J., and Wicks, I. (2016) Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway. Clin. Transl. Immunology 5, e79
38. Teijaro, J. R., Studer, S., Leaf, N., Kiosses, W. B., Nguyen, N., Matsuki, K., Negishi, H., Taniguchi, T., Oldstone, M. B. A., and Rosen, H. (2016) S1PR1-mediated IFNAR1 degradation modulates plasmacytoid dendritic cell interferon-α autoamplification. Proc. Natl. Acad. Sci. U.S.A. 113, 1351-1356
39. Pan, M., Kalie, E., Scaglione, B. J., Raveche, E. S., Schreiber, G., and Langer, J. A. (2008) Mutation of the IFNAR-1 receptor binding site of human IFN-α2 generates type I IFN competitive antagonists. Biochemistry 47, 12018-12027
40. Levin, D., Schneider, W. M., Hoffmann, H. H., Yarden, G., Busetto, A. G., Manor, O., Sharma, N., Rice, C. M., and Schreiber, G. (2014) Multifaceted activities of type I interferon are revealed by a receptor antagonist. Sci. Signal 7, ra50
41. Urin, V., Levin, D., Sharma, N., Harari, D., and Schreiber, G. (2015) Fine tuning of a type 1 interferon antagonist. PLoS ONE 10, e0130797
42. Wagner, T. C., Velichko, S., Chesney, S. K., Biroc, S., Harde, D., Vogel, D., and Croze, E. (2004) Interferon receptor expression regulates the antiproliferative effects of interferons on cancer cells and solid tumors. Int. J. Cancer 111, 32-42
43. Katlinskaya, Y. V., Katlinski, K. V., Yu, Q., Ortiz, A., Beiting, D. P., Brice, A., Davar, D., Sanders, C., Kirkwood, J. M., Rui, H., Xu, X., Koumenis, C., Diehl, J. A., and Fuchs, S. Y. (2016) Suppression of type I interferon signaling overcomes oncogene-induced senescence and mediates melanoma development and progression. Cell Rep. 15, 171-180
44. Chiantore, M. V., Vannucchi, S., Accardi, R., Tommasino, M., Percario, Z. A., Vaccari, G., Affabris, E., Fiorucci, G., and Romeo, G. (2012) Interferon-β induces cellular senescence in cutaneous human papilloma virus-transformed human keratinocytes by affecting p53 transactivating activity. PLoS ONE 7, e36909
45. Booy, S., van Eijck, C. H. J., Dogan, F., van Koetsveld, P. M., and Hofland, L. J. (2014) Influence of type-I interferon receptor expression level on the response to type-I interferons in human pancreatic cancer cells. J. Cell. Mol. Med. 18, 492-502
46. Bhattacharya, S., HuangFu, W. C., Dong, G., Qian, J., Baker, D. P., Karar, J., Koumenis, C., Diehl, J. A., and Fuchs, S. Y. (2013) Anti-tumorigenic effects of Type 1 interferon are subdued by integrated stress responses. Oncogene 32, 4214-4221
47. Fuchs, S. Y. (2013) Hope and fear for interferon: the receptor-centric outlook on the future of interferon therapy. J. Interferon Cytokine Res. 33, 211-225
48. Picaud, S., Bardot, B., De Maeyer, E., and Seif, I. (2002) Enhanced tumor development in mice lacking a functional type I interferon receptor. J. Interferon Cytokine Res. 22, 457-462
49. Moraga, I., Harari, D., Schreiber, G., Uzé, G., and Pellegrini, S. (2009) Receptor density is key to the α2/β interferon differential activities. Mol. Cell. Biol. 29, 4778-4787
50. Kalie, E., Jaitin, D. A., Podoplelova, Y., Piehler, J., and Schreiber, G. (2008) The stability of the ternary interferon-receptor complex rather than the affinity to the individual subunits dictates differential biological activities. J. Biol. Chem. 283, 32925-32936
51. Stark, G. R., and Darnell, J. E., Jr. (2012) The JAK-STAT pathway at twenty. Immunity 36, 503-514
52. Li, X., Leung, S., Kerr, I. M., and Stark, G. R. (1997) Functional subdomains of STAT2 required for preassociation with the α interferon receptor and for signaling. Mol. Cell. Biol. 17, 2048-2056
53. Leung, S., Qureshi, S. A., Kerr, I. M., Darnell, J. E., Jr., and Stark, G. R. (1995) Role of STAT2 in the α interferon signaling pathway. Mol. Cell. Biol. 15, 1312-1317
54. Romero-Weaver, A. L., Wang, H.-W., Steen, H. C., Scarzello, A. J., Hall, V. L., Sheikh, F., Donnelly, R. P., and Gamero, A. M. (2010) Resistance to IFN-α-induced apoptosis is linked to a loss of STAT2. Mol. Cancer Res. 8, 80-92
55. Veals, S. A., Schindler, C., Leonard, D., Fu, X. Y., Aebersold, R., Darnell, J. E., Jr., and Levy, D. E. (1992) Subunit of an α-interferon-responsive transcription factor is related to interferon regulatory factor and Myb families of DNA-binding proteins. Mol. Cell. Biol. 12, 3315-3324
56. Testoni, B., Völlenkle, C., Guerrieri, F., Gerbal-Chaloin, S., Blandino, G., and Levrero, M. (2011) Chromatin dynamics of gene activation and repression in response to interferon α (IFNα) reveal new roles for phosphorylated and unphosphorylated forms of the transcription factor STAT2. J. Biol. Chem. 286, 20217-20227
57. Blaszczyk, K., Nowicka, H., Kostyrko, K., Antonczyk, A., Wesoly, J., and Bluyssen, H. A. R. (2016) The unique role of STAT2 in constitutive and IFN-induced transcription and antiviral responses. Cytokine Growth Factor Rev. 29, 71-81
58. Blaszczyk, K., Olejnik, A., Nowicka, H., Ozgyin, L., Chen, Y.-L., Chmielewski, S., Kostyrko, K., Wesoly, J., Balint, B. L., Lee, C.-K., and Bluyssen, H. A. R. (2015) STAT2/IRF9 directs a prolonged ISGF3-like transcriptional response and antiviral activity in the absence of STAT1. Biochem. J. 466, 511-524
59. George, C. X., Das, S., and Samuel, C. E. (2008) Organization of the mouse RNA-specific adenosine deaminase Adar1 gene 5′-region and demonstration of STAT1-independent, STAT2-dependent transcriptional activation by interferon. Virology 380, 338-343
60. Perry, S. T., Buck, M. D., Lada, S. M., Schindler, C., and Shresta, S. (2011) STAT2 mediates innate immunity to Dengue virus in the absence of STAT1 via the type I interferon receptor. PLoS Pathog. 7, e1001297
61. Kraus, T. A., Lau, J. F., Parisien, J. P., and Horvath, C. M. (2003) A hybrid IRF9-STAT2 protein recapitulates interferon-stimulated gene expression and antiviral response. J. Biol. Chem. 278, 13033-13038
62. Bluyssen, H. A. R., and Levy, D. E. (1997) Stat2 is a transcriptional activator that requires sequence-specific contacts provided by Stat1 and p48 for stable interaction with DNA. J. Biol. Chem. 272, 4600-4605
63. Majoros, A., Platanitis, E., Szappanos, D., Cheon, H., Vogl, C., Shukla, P., Stark, G. R., Sexl, V., Schreiber, R., Schindler, C., Müller, M., and Decker, T. (2016) Response to interferons and antibacterial innate immunity in the absence of tyrosine-phosphorylated STAT1. EMBO Rep. 17, 367-382
64. Kaur, S., Kroczynska, B., Sharma, B., Sassano, A., Arslan, A. D., Majchrzak-Kita, B., Stein, B. L., McMahon, B., Altman, J. K., Su, B., Calogero, R. A., Fish, E. N., and Platanias, L. C. (2014) Critical roles for Rictor/Sin1 complexes in interferon-dependent gene transcription and generation of antiproliferative responses. J. Biol. Chem. 289, 6581-6591
65. Apelbaum, A., Yarden, G., Warszawski, S., Harari, D., and Schreiber, G. (2013) Type I interferons induce apoptosis by balancing cFLIP and Caspase-8 independent of death ligands. Mol. Cell. Biol. 33, 800-814
66. Ho, J., Pelzel, C., Begitt, A., Mee, M., Elsheikha, H. M., Scott, D. J., and Vinkemeier, U. (2016) STAT2 is a pervasive cytokine regulator due to its inhibition of STAT1 in multiple signaling pathways. PLoS Biol. 14, e2000117
67. Jaitin, D. A., and Schreiber, G. (2007) Upregulation of a small subset of genes drives type I interferon-induced antiviral memory. J. Interferon Cytokine Res. 27, 653-664
68. Cheon, H., and Stark, G. R. (2009) Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes. Proc. Natl. Acad. Sci. U.S.A. 106, 9373-9378
69. Cheon, H., Holvey-Bates, E. G., Schoggins, J. W., Forster, S., Hertzog, P., Imanaka, N., Rice, C. M., Jackson, M. W., Junk, D. J., and Stark, G. R. (2013) IFNβ-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage. EMBO J. 32, 2751-2763
70. Gupta, S., Jiang, M., and Pernis, A. B. (1999) IFN-α activates Stat6 and leads to the formation of Stat2:Stat6 complexes in B cells. J. Immunol. 163, 3834-3841
71. Wang, W. B., Levy, D. E., and Lee, C. K. (2011) STAT3 negatively regulates type I IFN-mediated antiviral response. J. Immunol. 187, 2578-2585
72. Zhao, L.-J., He, S.-F., Wang, W., Ren, H., and Qi, Z.-T. (2016) Interferon α antagonizes STAT3 and SOCS3 signaling triggered by hepatitis C virus. Cytokine 80, 48-55
73. Ray, J. P., Marshall, H. D., Laidlaw, B. J., Staron, M. M., Kaech, S. M., and Craft, J. (2014) Transcription factor STAT3 and type I interferons are corepressive insulators for differentiation of follicular helper and T helper 1 cells. Immunity 40, 367-377
74. Icardi, L., Mori, R., Gesellchen, V., Eyckerman, S., De Cauwer, L., Verhelst, J., Vercauteren, K., Saelens, X., Meuleman, P., Leroux-Roels, G., De Bosscher, K., Boutros, M., and Tavernier, J. (2012) The Sin3a repressor complex is a master regulator of STAT transcriptional activity. Proc. Natl. Acad. Sci. U.S.A. 109, 12058-12063
75. Tyler, D. R., Persky, M. E., Matthews, L. A., Chan, S., and Farrar, J. D. (2007) Pre-assembly of STAT4 with the human IFN-α/β receptor-2 subunit is mediated by the STAT4 N-domain. Mol. Immunol. 44, 1864-1872
76. Nguyen, K. B., Watford, W. T., Salomon, R., Hofmann, S. R., Pien, G. C., Morinobu, A., Gadina, M., O'Shea, J. J., and Biron, C. A. (2002) Critical role for STAT4 activation by type 1 interferons in the interferon-γ response to viral infection. Science 297, 2063-2066
77. Gil, M. P., Ploquin, M. J. Y., Watford, W. T., Lee, S.-H., Kim, K., Wang, X., Kanno, Y., O'Shea, J. J., and Biron, C. A. (2012) Regulating type 1 IFN effects in CD8 T cells during viral infections: changing STAT4 and STAT1 expression for function. Blood 120, 3718-3728
78. Fish, E. N., Uddin, S., Korkmaz, M., Majchrzak, B., Druker, B. J., and Platanias, L. C. (1999) Activation of a CrkL-Stat5 signaling complex by type I interferons. J. Biol. Chem. 274, 571-573
79. Uddin, S., Lekmine, F., Sassano, A., Rui, H., Fish, E. N., and Platanias, L. C. (2003) Role of Stat5 in Type I interferon-signaling and transcriptional regulation. Biochem. Biophys. Res. Commun. 308, 325-330
80. van Boxel-Dezaire, A. H., Zula, J. A., Xu, Y., Ransohoff, R. M., Jacobberger, J. W., and Stark, G. R. (2010) Major differences in the responses of primary human leukocyte subsets to IFN-β. J. Immunol. 185, 5888-5899
81. Hsu, Y. A., Huang, C. C., Kung, Y. J., Lin, H. J., Chang, C. Y., Lee, K. R., and Wan, L. (2016) The anti-proliferative effects of type I IFN involve STAT6-mediated regulation of SP1 and BCL6. Cancer Lett. 375, 303-312
82. Katsoulidis, E., Li, Y., Mears, H., and Platanias, L. C. (2005) The p38 mitogen-activated protein kinase pathway in interferon signal transduction. J. Interferon Cytokine Res. 25, 749-756
83. Saleiro, D., Mehrotra, S., Kroczynska, B., Beauchamp, E. M., Lisowski, P., Majchrzak-Kita, B., Bhagat, T. D., Stein, B. L., McMahon, B., Altman, J. K., Kosciuczuk, E. M., Baker, D. P., Jie, C., Jafari, N., Thompson, C. B., et al. (2015) Central role of ULK1 in type I interferon signaling. Cell Rep. 11, 605-617
84. Thyrell, L., Hjortsberg, L., Arulampalam, V., Panaretakis, T., Uhles, S., Dagnell, M., Zhivotovsky, B., Leibiger, I., Grandér, D., and Pokrovskaja, K. (2004) Interferon α-induced apoptosis in tumor cells is mediated through the phosphoinositide 3-kinase/mammalian target of rapamycin signaling pathway. J. Biol. Chem. 279, 24152-24162
85. Hjortsberg, L., Lindvall, C., Corcoran, M., Arulampalam, V., Chan, D., Thyrell, L., Nordenskjold, M., Grandér, D., and Pokrovskaja, K. (2007) Phosphoinositide 3-kinase regulates a subset of interferon-α-stimulated genes. Exp. Cell Res. 313, 404-414
86. de Weerd, N. A., and Nguyen, T. (2012) The interferons and their receptors: distribution and regulation. Immunol. Cell Biol. 90, 483-491
87. Bhattacharya, S., Katlinski, K. V., Reichert, M., Takano, S., Brice, A., Zhao, B., Yu, Q., Zheng, H., Carbone, C. J., Katlinskaya, Y. V., Leu, N. A., McCorkell, K. A., Srinivasan, S., Girondo, M., Rui, H., et al. (2014) Triggering ubiquitination of IFNAR1 protects tissues from inflammatory injury. EMBO Mol. Med. 6, 384-397
88. Kumar, K. G., Barriere, H., Carbone, C. J., Liu, J., Swaminathan, G., Xu, P., Li, Y., Baker, D. P., Peng, J., Lukacs, G. L., and Fuchs, S. Y. (2007) Sitespecific ubiquitination exposes a linear motif to promote interferon-α receptor endocytosis. J. Cell Biol. 179, 935-950
89. Kumar, K. G., Varghese, B., Banerjee, A., Baker, D. P., Constantinescu, S. N., Pellegrini, S., and Fuchs, S. Y. (2008) Basal ubiquitin-independent internalization of interferon α receptor is prevented by Tyk2-mediated masking of a linear endocytic motif. J. Biol. Chem. 283, 18566-18572
90. Liu, J., Plotnikov, A., Banerjee, A., Suresh Kumar, K. G., Ragimbeau, J., Marijanovic, Z., Baker, D. P., Pellegrini, S., and Fuchs, S. Y. (2008) Ligandindependent pathway that controls stability of interferon α receptor. Biochem. Biophys. Res. Commun. 367, 388-393
91. Chmiest, D., Sharma, N., Zanin, N., Viaris de Lesegno, C., Shafaq-Zadah, M., Sibut, V., Dingli, F., Hupé, P., Wilmes, S., Piehler, J., Loew, D., Johannes, L., Schreiber, G., and Lamaze, C. (2016) Spatiotemporal control of interferon-induced JAK/STAT signaling and gene transcription by the retromer complex. Nat. Commun. 7, 13476
92. Marchetti, M., Monier, M. N., Fradagrada, A., Mitchell, K., Baychelier, F., Eid, P., Johannes, L., and Lamaze, C. (2006) Stat-mediated signaling induced by type I and type II interferons (IFNs) is differentially controlled through lipid microdomain association and clathrin-dependent endocytosis of IFN receptors. Mol. Biol. Cell 17, 2896-2909
93. Malakhova, O. A., Kim, K. I., Luo, J. K., Zou, W., Kumar, K. G., Fuchs, S. Y., Shuai, K., and Zhang, D. E. (2006) UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity. EMBO J. 25, 2358-2367
94. Arimoto, K. I., Löchte, S., Stoner, S. A., Burkart, C., Zhang, Y., Miyauchi, S., Wilmes, S., Fan, J. B., Heinisch, J. J., Li, Z., Yan, M., Pellegrini, S., Colland, F., Piehler, J., and Zhang, D. E. (2017) STAT2 is an essential adaptor in USP18-mediated suppression of type I interferon signaling. Nat. Struct. Mol. Biol. 24, 279-289
95. François-Newton, V., Magno de Freitas Almeida, G., Payelle-Brogard, B., Monneron, D., Pichard-Garcia, L., Piehler, J., Pellegrini, S., and Uzé, G. (2011) USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon α response. PLoS ONE 6, e22200
96. Francois-Newton, V., Livingstone, M., Payelle-Brogard, B., Uzé, G., and Pellegrini, S. (2012) USP18 establishes the transcriptional and anti-proliferative interferon-/-differential. Biochem. J. 446, 509-516
97. Goldmann, T., Zeller, N., Raasch, J., Kierdorf, K., Frenzel, K., Ketscher, L., Basters, A., Staszewski, O., Brendecke, S. M., Spiess, A., Tay, T. L., Kreutz, C., Timmer, J., Mancini, G. M. S., Blank, T., et al. (2015) USP18 lack in microglia causesdestructiveinterferonopathyofthemousebrain.EMBOJ.34,1612-1629
98. Speer, S. D., Li, Z., Buta, S., Payelle-Brogard, B., Qian, L., Vigant, F., Rubino, E., Gardner, T. J., Wedeking, T., Hermann, M., Duehr, J., Sanal, O., Tezcan, I., Mansouri, N., Tabarsi, P., et al. (2016) ISG15 deficiency and increased viral resistance in humans but not mice. Nat. Commun. 7, 11496
99. Piganis, R. A., De Weerd, N. A., Gould, J. A., Schindler, C. W., Mansell, A., Nicholson, S. E., and Hertzog, P. J. (2011) Suppressor of cytokine signaling (SOCS) 1 inhibits type I interferon (IFN) signaling via the interferon α receptor (IFNAR1)-associated tyrosine kinase Tyk2. J. Biol. Chem. 286, 33811-33818
100. Linossi, E. M., and Nicholson, S. E. (2015) Kinase inhibition, competitive binding and proteasomal degradation: resolving the molecular function of the suppressor of cytokine signaling (SOCS) proteins. Immunol. Rev. 266, 123-133